HemoSonics’ Quantra Hemostasis System provides comprehensive blood analysis detailing hemostasis in the operating room in less than 15 minutes – a diagnostic breakthrough improving healthcare outcomes
DURHAM, N.C.–(BUSINESS WIRE)–#BioTech—HemoSonics, LLC, a medical device company focused on acute bleeding management, today announced the company has won the Triangle Business Journal 2025 Life Sciences Award in the Best Medical Device Company category for its Quantra Hemostasis System’s groundbreaking work in viscoelastic testing. HemoSonics’ Quantra Hemostasis System speeds up decision-making in the operating room, improves patient outcomes and reduces healthcare costs by providing optimized coagulation information.
According to data from the North Carolina Biotechnology Center, North Carolina is home to 840 life sciences companies, with the lion’s share based in the Triangle. The Triangle Business Journal’s Life Sciences Awards recognize 12 individuals and research organizations from the Research Triangle, North Carolina (Raleigh, Durham and Chapel Hill region) that are leading and breaking ground in this field. The broad spectrum of the life sciences arena encompasses biotechnology, pharmaceuticals, clinical research, human health, medical devices and diagnostics, and other related fields.
The HemoSonics Quantra Hemostasis System consists of the Quantra Hemostasis Analyzer, along with QPlus and QStat Cartridges. The System provides fast, comprehensive whole-blood coagulation analysis at the point of care or in laboratory settings in under 15 minutes, empowering clinicians with information to inform patient-centered decisions that improve care and optimize blood product usage. The Quantra System uses innovative SEER Sonorheometry (Sonic Estimation of Elasticity via Resonance), a proprietary medical-grade ultrasound technology that measures the coagulation properties of a whole blood sample.
HemoSonics’ Quantra System is FDA-cleared for cardiovascular surgery, trauma, liver transplantation, and major orthopedic surgery. It requires minimal resources to maintain, is easy to operate and interpret, and enables hospitals to standardize a clinically and operationally efficient viscoelastic testing program.
“The Research Triangle Park has long been recognized as a catalyst for pioneering technologies in biotechnology, medical devices, and health technology, and this community is one of the key reasons we chose Durham for our headquarters,” said Bob Roda, HemoSonics President and CEO. “Innovation is at the heart of what we do at HemoSonics, and we’re thrilled to be mentioned alongside companies who are changing the world for the better through medical and scientific advances.”
HemoSonics’ Quantra Hemostasis System technology has received numerous accolades, including the 2024 TIME Best Inventions, 2024 Fast Company Most Innovative Companies (Medtech), 2024 Edison Awards (Point-of-Care and Therapeutic Solutions), and the 2024 Deloitte Fast 500, which recognizes the fastest-growing companies in North America.
About HemoSonics:
HemoSonics, LLC is a medical device technology company focused on acute bleeding management, resulting in better patient care and lower overall medical costs. The Quantra Hemostasis Analyzer, HemoSonics’ flagship product, is designed to improve patient outcomes and reduce healthcare costs by providing optimized coagulation information. The Quantra System’s easy and fast interpretation enables simple, more efficient point-of-care and laboratory bleeding management.
Based in Durham, North Carolina, HemoSonics is part of the Stago Group, a leading in vitro diagnostics company dedicated to exploring thrombosis and hemostasis. Visit HemoSonics.com to learn more.
Contacts
Media Contacts:
Mindy M. Hull
Mercury Global Partners for HemoSonics
+1 415 889 9977 (San Francisco)
hemosonics@wearemgp.com
Michael Held-Hernandez
Mercury Global Partners for HemoSonics
+1 480 306 1154 (Washington D.C.)
hemosonics@wearemgp.com
Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…
Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…
Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…
Science-Backed Spermidine Ritual Brings Cellular Renewal to a High-Performance Cultural Moment Primeadine Longevity Shot Primeadine…
CRANFORD, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or…
MINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Park Dental Partners, Inc. (NASDAQ: PARK), a leading…
